Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Abstract Background Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to...

Full description

Bibliographic Details
Main Authors: Sara Valpione, Sandro Pasquali, Luca Giovanni Campana, Luisa Piccin, Simone Mocellin, Jacopo Pigozzo, Vanna Chiarion-Sileni
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Journal of Translational Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12967-018-1467-x